Giltiay, N. V., Shu, G. L., Shock, A., & Clark, E. A. (2017). Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling. Arthritis Res Ther.
Chicago-стиль цитированияGiltiay, Natalia V., Geraldine L. Shu, Anthony Shock, and Edward A. Clark. "Targeting CD22 With the Monoclonal Antibody Epratuzumab Modulates Human B-cell Maturation and Cytokine Production in Response to Toll-like Receptor 7 (TLR7) and B-cell Receptor (BCR) Signaling." Arthritis Res Ther 2017.
MLA-цитированиеGiltiay, Natalia V., Geraldine L. Shu, Anthony Shock, and Edward A. Clark. "Targeting CD22 With the Monoclonal Antibody Epratuzumab Modulates Human B-cell Maturation and Cytokine Production in Response to Toll-like Receptor 7 (TLR7) and B-cell Receptor (BCR) Signaling." Arthritis Res Ther 2017.